Definiens and Clarient sign agreement over image analysis software

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

DEFINIENS and Clarient Diagnostic Services Inc. signed an agreement to extend the use of Definiens’ automated image analysis software and solutions in Clarient’s validated clinical applications for immunohistochemistry testing in breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login